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ABSTRACT
Objectives Heterogeneity in outcomes measured across 
trials of glucose- lowering interventions for people with 
type 2 diabetes impacts on the ability to compare findings 
and may mean that the results have little importance to 
healthcare professionals and the patients that they care 
for. The SCORE- IT study (Selecting Core Outcomes for 
Randomised Effectiveness trials In Type 2 diabetes) has 
addressed this issue by establishing consensus on the 
most important outcomes for non- surgical interventions for 
hyperglycemia in type 2 diabetes.
Research design and methods A comprehensive list of 
outcomes was developed from registered clinical trials, 
online patient resources, qualitative literature and long- 
term studies in the field. This list was then scored in a 
two- round online Delphi survey completed by healthcare 
professionals, people with type 2 diabetes, researchers in 
the field and healthcare policymakers. The results of this 
online Delphi were discussed and ratified at a face- to- face 
consensus meeting.
Results 173 people completed both rounds of the online 
survey (116 people with type 2 diabetes, 37 healthcare 
professionals, 14 researchers and 6 policymakers), 20 
of these attended the consensus meeting (13 people 
with type 2 diabetes and 7 healthcare professionals). 
Consensus was reached on 18 core outcomes across 
five domains, which include outcomes related to diabetes 
care, quality of life and long- term diabetes- related 
complications.
Conclusions Implementation of the core outcome set in 
future trials will ensure that outcomes of importance to all 
stakeholders are measured and reported, enhancing the 
relevance of trial findings and facilitating the comparison 
of results across trials.
BaCkgROund
Type 2 diabetes is a global pandemic. Current 
estimates indicate that 623 million people 
aged 20–79 will be affected by diabetes by 
2045, with the majority of these cases being 
type 2 diabetes.1–3
Treatment for type 2 diabetes is targeted 
at the hyperglycemia arising due to a resis-
tance to insulin action and an inadequate 
Significance of this study
What is already known about this subject?
 ► A systematic review of active clinical trials regis-
tered with ClinicalTrials.gov identified marked het-
erogeneity in the outcomes measured in trials of 
glucose- lowering interventions for people with type 
2 diabetes.
 ► This inconsistency in outcomes impacts on the 
ability to compare findings and may mean that the 
results have little importance to healthcare profes-
sionals and the patients that they care for.
What are the new findings?
 ► Eighteen outcomes have been included in the 
SCORE- IT (Selecting Core Outcomes for Randomised 
Effectiveness trials In Type 2 diabetes) core outcome 
set, across five domains, which reflect outcomes 
related to diabetes care, quality of life and diabetes- 
related complications.
 ► This core outcome set has been developed with in-
put from all stakeholders including people with type 
2 diabetes, healthcare professionals, researchers in 
the field and healthcare policymakers/payers, and 
has ensured that all participants had an equal voice 
when deciding the most important outcomes.
How might these results change the focus of 
research or clinical practice?
 ► Implementation of the SCORE- IT core outcome set 
in future clinical trials, of glucose- lowering interven-
tions, will increase the relevance of research to all 
stakeholders and will allow results from different 
trials to be more easily compared and combined.
 ► This increased potential for meta- analysis will en-
able new, effective treatments to be made available 
to people with type 2 diabetes more quickly.
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insulin secretory response.4 5 Lifestyle changes or phar-
macotherapy aim to control blood glucose levels and 
avoid hyperglycemia and associated long- term compli-
cations,6–12 and these may also be supplemented with 
bariatric surgical intervention.13
A recent review of open (actively recruiting or in 
follow- up period), phase III and IV trials registered with 
ClinicalTrials. gov identified considerable variation in the 
outcomes measured and reported for glucose- lowering 
therapies in people with type 2 diabetes.14 This variation 
may impact on the ability to compare studies and hinder 
evidence synthesis, contributing to waste in research.15 
Furthermore, of the outcomes measured in the included 
trials, only 10% represented patient- reported outcomes. 
It is possible to address these issues and to increase the 
relevance of research by developing a core outcome 
set (COS), representing an agreed standardized set of 
outcomes that should be measured and reported in all 
trials for a specific clinical area.16 To date only two studies 
have investigated important outcomes for diabetes. Byrne 
et al17 have developed a COS for young adults with type 1 
diabetes, and Murad et al18 explored outcomes important 
to patients with diabetes using a single item on a ques-
tionnaire that ranked a list of 10 outcomes.
The aim of the SCORE- IT study (Selecting Core 
Outcomes for Randomised Effectiveness trials In Type 2 
diabetes) was to address this gap in outcomes research 
and develop a COS for use in clinical trials of non- surgical 
therapeutic interventions for the treatment of hypergly-
cemia in adults with type 2 diabetes that includes input 
from all stakeholders.
MeTHOds
study overview
The development of the COS involved three stages 
(figure 1): (1) the generation of a long list of outcomes 
for use in an online Delphi; (2) a two- round online 
Delphi survey with key stakeholders; and (3) a face- to- face 
consensus meeting to discuss the results of the Delphi 
survey and agree on the COS. The methods for each step 
are described briefly below. A study protocol, systematic 
review and qualitative review describing methods in full 
have been published elsewhere.14 19 20
Outcome list generation
The list of outcomes was generated from a number of 
sources19: a systematic review of open trials registered 
with  ClinicalTrials. gov, a rapid review of the qualitative 
literature and extraction of outcomes from patient expe-
riences reported on HealthTalk Online ( www. healthtalk. 
org). The detailed search strategies for  ClinicalTrials. 
gov and for the qualitative review have been published 
elsewhere.14 20 In addition to these sources, outcomes 
were extracted from transcripts of video clips of adults 
aged 18 years and over with type 2 diabetes who shared 
their experience on the publicly available HealthTalk 
online website.21 The Study Steering Committee (SSC) 
also provided a list of long- term cardiovascular outcome 
studies in people with type 2 diabetes from which 
outcomes were extracted.22–33 Outcomes were extracted 
verbatim, for each source, before being grouped using a 
standardized outcome name and categorized according 
to the taxonomy of Dodd et al.34 The list was cross- 
checked against outcomes and domains included in the 
patient- reported outcome measures (PROMs) identified 
by Reaney et al,35 the BIRO (Best Information through 
Regional Outcomes) common data set for diabetes ( www. 
eubirod. eu) and relevant Cochrane reviews. To identify 
relevant reviews the Cochrane database of systematic 
reviews was searched for “type 2 diabetes” in the “title,” 
“abstract” and “key words” fields. The resulting list of 
outcomes was reviewed by the SSC and outcomes further 
grouped or excluded if measured in a single study and/
or considered to be of limited clinical importance to 
glucose- lowering interventions. Each outcome was 
written using plain language and feedback sought from 
the public contributor members of the SSC on the accept-
ability and their understanding of the wording used.
Online delphi survey of stakeholders
The long list of outcomes was used to populate an online 
Delphi survey, delivered using the DelphiManager plat-
form.36 Participants were invited from four key stake-
holder groups: people with type 2 diabetes and their 
carers; healthcare professionals involved in delivering 
care for people with type 2 diabetes; researchers in the 
field; and healthcare policymakers/payers. Invitations to 
participate were shared with national and international 
patient and professional organizations, which were asked 
to distribute the invitations to their members (online 
supplementary file 1). We also approached the lead 
contact of the studies included in the  ClinicalTrials. gov 
review, authors of relevant Cochrane reviews, researchers 
in receipt of funding from a large UK diabetes charity, 
and program leads at the National Institute of Diabetes 
and Digestive and Kidney Diseases of the National Insti-
tutes of Health and UK- based diabetes research centers. 
Finally, health professionals in the UK were contacted via 
the Wilmington’s UK database of health professionals. 
Policymakers were identified through the International 
Network of Agencies for Health Technology Assessment 
(INAHTA) members list and organizations approached 
individually.
The Delphi process was completed using two rounds 
(termed R1 and R2). In each round participants were 
presented with the list of outcomes and asked to score 
each outcome on how important it was to include in the 
COS, using a 9- point Likert scale presented in formats 
1–9, with 1–3 labeled “not important,” 4–6 labeled 
“important but not critical,” and 7–9 labeled “critically 
important.”37 At the end of R1, participants were invited 
to submit additional outcomes, and these outcomes were 
reviewed by the SSC and any suggestions representing 
a new outcome added to the list to be scored in R2. 
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Figure 1 Core outcome set development overview. SSC, Study Steering Committee.
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Table 1 Definition of consensus
Consensus classification Description Definition
Consensus in Consensus that outcome should be 
included in the core outcome set.
70% or more participants in each stakeholder group 
scoring as 7–9 and <15% participants in each stakeholder 
group scoring as 1–3.
Consensus out Consensus that outcome should not 
be included in the core outcome set.
50% or fewer participants scoring 7–9 in each stakeholder 
group.
No consensus Uncertainty about the importance of 
outcome.
Anything else.
Outcomes were not removed from the list between R1 
and R2.
During R2, participants were shown the distribution 
of scores for each stakeholder group for each outcome 
together with their own score from R1 and asked to score 
the outcome again, using the same 1–9 Likert scale, 
taking this information into consideration.
Consensus meeting
A face- to- face consensus meeting was held in Liverpool, 
UK, and the results of the online Delphi survey were 
presented. Participants who had completed both R1 
and R2 of the Delphi were invited to attend. Prior to the 
meeting, participants received a copy of their scores from 
the online survey and a consensus matrix detailing the 
results of R2 by stakeholder group (online supplementary 
file 2) and which outcomes had reached the predefined 
definition of consensus “in” or consensus “out” (table 1).
The meeting was chaired by an independent non- 
clinical researcher with expertise in COS development 
methodology. Outcomes that had reached consensus “in” 
after R2 in all four stakeholder groups were presented 
first, followed by outcomes that had reached consensus 
“out” after R2 in all four stakeholder groups. Meeting 
participants were asked if they disagreed with the inclu-
sion or exclusion of these items from the COS, respec-
tively. All outcomes with two or more stakeholder groups 
reaching consensus “in” were discussed, outcomes with 
one stakeholder group reaching consensus “in” were 
shown to meeting participants, and participants asked 
if any of these should be discussed. Outcomes with no 
consensus and no group scoring consensus “in” were not 
discussed.
Views for and against inclusion in the COS were sought 
by the meeting chair, who also ensured that participants 
had equal opportunity to comment prior to voting. Voting 
took place anonymously using the TurningPoint software 
and handsets (Turning Technologies, Youngstown, USA). 
Following voting the results were displayed to participants 
by stakeholder group. For the purpose of the consensus 
meeting, stakeholder groups were condensed to health-
care professionals (this group included researchers in 
the field who also had a clinical role) and people with 
type 2 diabetes. Healthcare policymakers were present 
to provide their perspective and contribute to the discus-
sions. The definition of consensus used in the Delphi 
survey (table 1) was applied with both groups required to 
reach the definition of consensus “in” for the outcome to 
be included in the COS. The final COS was presented at 
the end of the meeting and also included in a summary 
sent to participants after the meeting.
Other analyses
Attrition bias between R1 and R2 of the online Delphi 
was assessed by comparing the distribution of mean R1 
scores for participants completing R1 only and partici-
pants completing both R1 and R2. Satisfaction with the 
consensus meeting process, organization and outcome 
was assessed using a questionnaire (online supplemen-
tary file 3).
study registration and study oversight
The SCORE- IT study was prospectively registered with the 
COMET Initiative (Core Outcome Measures in Effective-
ness Trials).38 The SSC composition has been described 
previously.19 The SCORE- IT study is reported in line 
with the Core Outcome Set – Standards for Reporting 
reporting guidance.39
ResulTs
An overview of the SCORE- IT COS development process 
and final COS is shown in figure 1. The final COS includes 
18 outcomes across five domains (table 2).
development of the long list of outcomes
The systematic review of clinical trials and the rapid 
review of qualitative studies have been presented in 
detail elsewhere.14 The review of clinical trials yielded 
1444 individual outcomes and the qualitative review 474. 
These were combined with 409 outcomes from the long- 
term cardiovascular outcome studies and 232 outcomes 
identified from HealthTalk Online. The resulting 2560 
outcomes were reviewed and outcome names standard-
ized to give 223 outcomes. These 223 outcomes were 
reviewed against the remaining data sources. One addi-
tional outcome “hyperosmolar hyperglycaemic state” was 
identified from the review of outcomes used in Cochrane 
reviews and added to the long list. No further outcomes 
were identified from the BIRO data set or review of 
PROMs.35
The 223 outcomes were mapped onto a 38- category 
system and grouped under five domains (mortality n=5, 
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Table 2 Outcomes included in the SCORE- IT core outcome set
Outcome Domain
Glycemic control: how well someone’s blood glucose is controlled. Physiological/clinical
Global quality of life: someone’s overall quality of life, including physical, mental 
and social well- being.
Life impact
Activities of daily living: being able to complete usual everyday tasks and activities, 
including those related to personal care, household tasks or community- based 
tasks.
Life impact
Body weight: how much someone weighs. Physiological/clinical
Kidney function: how well someone’s kidneys are working. Physiological/clinical
Hyperglycemia: how often someone has high blood glucose. Physiological/clinical
Hypoglycemia: how often someone has low blood glucose levels. Physiological/clinical
Visual deterioration or blindness: if someone’s eyesight gets worse or if they have 
loss of vision including blindness.
Physiological/clinical
Neuropathy: damage to the nerves caused by high glucose. This can lead to 
tingling and pain or numbness in the feet or legs. It can also affect bowel control, 
stomach emptying and sexual function.
Physiological/clinical
Having gangrene or having an amputation of the leg, foot or toe. Physiological/clinical
Non- fatal myocardial infarction: having a heart attack that is not fatal. Physiological/clinical
Heart failure. Physiological/clinical
Cerebrovascular disease, including stroke, subarachnoid hemorrhage, transient 
ischemic attack and vascular dementia.
Physiological/clinical
How often someone is admitted to hospital because of their diabetes. Resource use
Hyperglycemic emergencies (to include diabetic ketoacidosis and hyperosmolar 
hyperglycemic state).
Physiological/clinical
Side effects of treatment: any unwanted effects of the treatment. Adverse events
Overall survival: how long someone lives. Death
Death from a diabetes- related cause, such as heart disease. Death
SCORE- IT, Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 diabetes.
life impact n=67, physiological/clinical n=127, resource 
use n=22 and adverse events n=2).34 These outcomes 
were then presented to the SSC, and after discussion 
64 outcomes (online supplementary file 4) were taken 
forward to the online Delphi.
Online delphi process
One hundred and seventy three participants completed 
both R1 and R2 of the online survey. Participants 
comprised 37 healthcare professionals, 116 people with 
type 2 diabetes or their carers, 14 researchers in the field 
and 6 healthcare policymakers (table 3).
At the end of R1, 10 outcomes met the predefined 
criteria for inclusion in the COS across all four stake-
holder groups. Fifty- one responses were received to 
the free- text question asking participants if there were 
any additional outcomes they would like to add. These 
outcomes were reviewed by the SSC and one outcome 
“gut microbiome - the type/number of bacteria in some-
one’s digestive tract” was added and scored by participants 
in R2. A further three outcomes (activities of daily living, 
satisfaction with treatment and care, and emotional well- 
being) were modified based on the free- text response to 
clarify the outcome.
At the end of R2 of the Delphi, nine outcomes had 
reached consensus, for inclusion in the COS, across all 
four stakeholder groups, and nine outcomes had reached 
the definition for exclusion from the COS (online supple-
mentary file 2).
Six outcomes reached the definition of “consensus in” 
in both R1 and R2 and have been included in the final 
COS.
The overall attrition rate between R1 and R2 was 25%, 
with the highest attrition rate observed for specialist/
practice nurses (table 4).
The impact of attrition between rounds was assessed 
by comparing the average R1 scores of those who did 
not complete R2 against the distribution of scores for 
those completing both R1 and R2. Overall the distribu-
tion of average scores of those who did not complete R2 
was similar to those completing both R1 and R2 for all 
stakeholder groups, suggesting that attrition bias was not 
present between rounds (online supplementary file 5).
Consensus meeting
Twenty participants attended the consensus meeting 
(7 healthcare professionals and 13 people with type 2 
diabetes); in addition to the 20 voting participants, there 
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Table 3 Characteristics of Delphi participants completing 
round 1 and round 2
n (%)
Healthcare professionals 37 (100)
Occupation
  Consultant 17 (21)
  Dietitian 7 (9)
  General practitioner 18 (23)
  Pharmacist 2 (3)
  Specialist nurse/practice nurse 36 (45)
Country of residence
  Austria 1 (3)
  Germany 1 (3)
  Greece 1 (3)
  India 1 (3)
  Mexico 1 (3)
  Singapore 1 (3)
  Switzerland 1 (3)
  UK 30 (81)
People with type 2 diabetes and their carers 116 (100)
Age (years)
  30–39 3 (3)
  40–49 8 (7)
  50–59 19 (16)
  60–69 55 (47)
  70–79 29 (25)
  >80 2 (2)
Country of residence
  Greece 1 (1)
  UK 115 (99)
  Researchers in the field 14 (100)
Country of residence
  Malaysia 2 (14)
  Singapore 1 (7)
  South Africa 1 (7)
  UK 9 (64)
  Not reported 1 (7)
Healthcare policymakers/payers 6 (100)
Country of residence
  Argentina 1 (17)
  Australia 1 (17)
  Austria 1 (17)
  Canada 1 (17)
  Germany 1 (17)
  Sweden 1 (17)
were 3 healthcare policymakers/payers who contrib-
uted to discussion along with members of the SSC. In 
the consensus meeting a further nine outcomes met 
the definition for inclusion in the COS, in addition to 
the nine outcomes that had reached the definition of 
consensus for inclusion at the end of R2 of the Delphi 
(online supplementary file 6). Of these outcomes, eight 
required further discussion by the SSC at a follow- up 
teleconference (online supplementary file 7). In addi-
tion to wording changes, one outcome “diabetic ketoaci-
dosis” was amended to “hyperglycaemic emergencies (to 
include diabetic ketoacidosis and hyperosmolar hypergly-
caemic state).” The SSC also reflected on the outcomes 
“hyperglycaemia,” how this had been interpreted by 
Delphi participants and that further discussion/think 
aloud work prior to launching the Delphi may have been 
needed. Finally, the SSC discussed the comment raised at 
the consensus meeting to add “prolongation of hospital 
stay” to the outcome “how often someone is admitted to 
hospital because of their diabetes.” All agreed that this 
was a separate outcome that had not been scored or 
added in the Delphi but is an important point for future 
discussion.
Feedback forms from the meeting were completed by 
4 (57%) healthcare professionals and 12 (92%) people 
with type 2 diabetes. All participants were satisfied with 
the way the meeting was facilitated, felt able to contribute 
to the meeting and felt comfortable expressing their 
views. In terms of the consensus meeting producing a 
fair result, one health professional felt that voting may 
have been influenced by a dominant participant, and one 
person with type 2 diabetes neither agreed nor disagreed 
with the statement.
disCussiOn
The SCORE- IT study has developed patient and health 
professional consensus on outcomes for trials of the treat-
ment of hyperglycemia in people with type 2 diabetes. 
The process to achieve consensus has ensured that all 
stakeholders including people with type 2 diabetes, 
healthcare professionals, researchers in the field and 
healthcare policymakers/payers have been able to 
contribute to the final COS. We recommend that future 
trials of interventions to treat hyperglycemia in people 
with type 2 diabetes use the SCORE- IT COS. This COS 
does not prevent other outcomes being measured, as 
appropriate to the intervention, but rather represents 
the minimum that should be measured.
Particular strengths of the SCORE- IT COS include 
the use of methods meeting the COS- STAD (Core 
Outcome Set - STAndards for Development) recommen-
dations,40 published in a study protocol prior to under-
taking the study.19 This study has also engaged multiple 
stakeholder groups including health professionals and 
people with type 2 diabetes to achieve consensus on 
the most important outcomes. Only 3% of COS to date 
have included input from healthcare policymakers,41 
the inclusion of policymakers in the present study has 
ensured that important outcomes used when evaluating 
the available evidence and making decisions are taken 
into consideration in the final COS. In the SCORE- IT 
Protected by copyright.
 o
n
 January 13, 2020 at University of G
lasgow.
http://drc.bmj.com/
BM
J O
pen Diab Res Care: first published as 10.1136/bmjdrc-2019-000700 on 29 December 2019. Downloaded from 
7BMJ Open Diab Res Care 2019;7:e000700. doi:10.1136/bmjdrc-2019-000700
Epidemiology/Health Services Research
Table 4 Attrition rates between rounds
Stakeholder
Registered, 
n (% of total 
registrations)
Withdrawn 
prior to 
completing R1
Withdrawn 
after R1 and 
before R2
Completed 
R1, n (% of 
registrations 
minus 
withdrawals 
before R1)
Completed 
R2, n (% of 
R1)
Healthcare professionals 80 (25) 0 0 56 (70) 37 (66)
Consultant 17 (5) 0 0 10 (59) 8 (80)
Dietitian 7 (2) 0 6 (86) 5 (83)
General practitioner 18 (6) 0 0 13 (72) 8 (62)
Pharmacist 2 (1) 0 0 2 (100) 2 (100)
Specialist/practice nurse 36 (11) 0 0 25 (69) 14 (56)
Researchers in the field 20 (6) 0 1 17 (85) 14 (88)
Policymakers/payers 9 (3) 0 0 7 (78) 6 (86)
People with type 2 diabetes or their 
carers
211 (66) 5 2 153 (74) 116 (77)
Carer 5 (2) 0 0 3 (60) 1 (33)
Patient 206 (64) 5 2 150 (75) 115 (78)
Total 320 5 3 233 (74) 173 (75)
R1, round 1; R2, round 2.
study members of the International Network of Agen-
cies for Health Technology Assessment (INAHTA) were 
approached with an invitation to take part. Of the 50 
members, six (12%) completed R1 and R2 suggesting 
that further work is needed to engage with HTA organ-
isations to facilitate the contribution of this stakeholder 
group to COS development.
Although this study has had some international input, 
engagement both in the UK and on an international 
level was challenging, with only one patient and a fifth 
of healthcare professionals and researchers combined 
based outside of the UK. We sought to improve interna-
tional input from people with type 2 diabetes through 
engagement with patient organizations and translation of 
the Delphi into the appropriate local language. However, 
despite Polish and Brazilian Portuguese versions being 
distributed, via direct email to members of patient orga-
nizations, participation was low, with only one person 
completing R1 of the Delphi in Polish. Choosing appro-
priate outcomes to measure is a top methodological 
priority for trialists working in low- income and middle- 
income countries (LMICs).42 A recent review found the 
number of COS being developed in some LMICs has 
increased,41 yet the number of participants in each COS, 
the methods of engagement and the source of recruit-
ment have yet to be explored. Further work is warranted 
in the field of COS research more generally on how 
best to engage stakeholders and facilitate participation 
nationally, internationally and particularly in countries 
where representation in the COS development process 
is low. For the SCORE- IT COS it will be important to 
evaluate the acceptability of the current COS to patients 
and professionals in other countries, particularly where 
healthcare systems differ from that in the UK.
The SCORE- IT COS is specific for type 2 diabetes, yet 
there is overlap with outcomes of importance to young 
adults with type 1 diabetes identified by Byrne et al.17 Of 
the eight outcomes in their COS, all three outcomes that 
are physiological/clinical are included in the current 
SCORE- IT COS.17 Quality of life is also common across 
the two COS, although in the study by Byrne et al17 this was 
amended to “diabetes related quality of life” in response 
to discussion at the consensus meeting. Other outcomes 
included in the COS for young adults with type 1 diabetes 
were included in the long list of outcomes scored in R1 of 
the present study, yet these outcomes did not reach the 
definition of consensus “in.” Self- management behavior, 
specifically “Diabetes self- care activities…”, was discussed 
further at the consensus meeting but did not reach 
the definition of consensus for inclusion in the COS. 
The SCORE- IT COS includes additional outcomes that 
reflect complications of hyperglycemia, which were not 
included in the COS developed by Byrne et al, suggesting 
that while there are some similarities the priorities of the 
stakeholders vary depending on the type of diabetes and 
the age group of participants.
Murad et al18 included participants with both type 
1 (5%) and type 2 (93%) in a survey to identify partic-
ipants’ top 5 outcomes from a list of 10. All 10 of the 
outcomes ranked were included in the current Delphi 
survey, and all, with the exception of the need for photo-
coagulation, scored in the present study as retinopathy, 
were included in the current COS, with hemoglobin A1c 
and end- stage renal disease included in the “glycaemic 
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control” and “kidney function” outcomes, respectively. 
The list of outcomes used by Murad et al18 was generated 
from a panel of eight patients and ranked by patients 
only. Our approach to the development of the outcomes 
list and engagement of people with type 2 diabetes, 
healthcare professionals and researchers have identified 
an additional 10 outcomes, including outcomes within 
the life impact domain (quality of life and activities of 
daily living), which are important to all stakeholders.
The International Consortium for Health Outcomes 
Measurement (ICHOM) has recently reported a stan-
dard set for diabetes in adults. The development of 
this standard set has included international input from 
26 experts (3 patients and 23 clinicians) and includes 
26 outcomes. Fifty- four percent of the ICHOM stan-
dard set is reflected in the SCORE- IT COS, with some 
subtle differences. Most notably the life impact outcomes 
between the two outcome sets differ. Psychological well- 
being, diabetes distress and depression are included in 
the ICHOM, while these outcomes, scored collectively in 
SCORE- IT as “Emotional wellbeing,” did not reach the 
definition of “consensus in” in any round of the Delphi 
survey. Instead participants of the SCORE- IT study rated 
“global quality of life” and “activities of daily living” as 
the most important life impact outcomes. Two outcomes 
in the ICHOM standard set, “periodontal health” and 
“emergency room utilisation,” were not included in the 
SCORE- IT Delphi list of outcomes. Periodontal health 
was not measured/identified from any of the sources 
used to generate the long list of outcomes, while the 
need to attend the emergency room was identified in the 
systematic review but measured only in a single study and 
not taken forward to the Delphi survey. Neither outcome 
was added to the list by Delphi participants completing 
R1 of the Delphi survey.
While there is substantial overlap between the ICHOM 
standard set and the SCORE- IT COS, differences may 
reflect the scope of the projects, clinical practice versus 
clinical trials, respectively, and may also be influenced by 
the methods used and the type, number and geographic 
location of the stakeholders involved. Nevertheless the 
overlap between studies is positive, and if outcomes are 
captured routinely in clinical practice then this may help 
improve the efficiency of clinical trials and reduce the 
burden to trial participants.
COnClusiOns
The COS developed in the SCORE- IT study can be 
applied to future clinical trials of non- surgical inter-
ventions to treat hyperglycemia, and its use will allow 
comparisons to take place across trials, thereby reducing 
waste in research. The next steps will include seeking 
consensus on how these outcomes should be measured 
and to provide this guidance to researchers.
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